Effects of Interferon on PD-1/PD-L1 and Treg Expression in JAK2 V617F-positive Myeloproliferative Neoplasms

Effects of Interferon on PD-1/PD-L1 and Treg Expression in JAK2 V617F-positive Myeloproliferative Neoplasms

Objective To explore the effect of interferon-alpha-2b(IFN-alpha 2b) on the expression of programmed death receptor-1(PD-1), programmed death ligand-1(PD-L1) and CD4+ CD25+ Foxp3+ regulatory T cell (Treg) in JAK2 V617F-positive myeloproliferative neoplasms(MPN) and related clinical significance. Met...

Full description

Bibliographic Details
Main Authors:	ZHANG Lijun, QI Feng, CHENG Zhiyong, ZHANG Zhao, WU Shijie, GUO Yantao, SUN Li'na, PENG Zhanxian, LIANG Wentong
Format:	Article
Language:	zho
Published:	Magazine House of Cancer Research on Prevention and Treatment 2019-01-01
Series:	Zhongliu Fangzhi Yanjiu
Subjects:	pd-1 pd-l-1 treg myeloproliferative neoplasms(mpn) interferon
Online Access:	http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.0937.htm

Similar Items

Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms
by: Steven De Almeida, et al.
Published: (2020-09-01)

PD-1/PD-L1 regulates Treg differentiation in pregnancy-induced hypertension
by: Lai Jiang, et al.
Published: (2018-05-01)

The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
by: Cai J, et al.
Published: (2019-10-01)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
by: Ziqi Wan, et al.
Published: (2020-10-01)

Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression
by: Elena Gianchecchi, et al.
Published: (2018-10-01)

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
by: Kazushige Yoshida, et al.
Published: (2020-01-01)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
by: Xiaoqiang Liu, et al.
Published: (2019-12-01)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4<sup>+</sup> T Cells
by: Reem Saleh, et al.
Published: (2019-10-01)

Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response
by: Morten Orebo Holmström, et al.
Published: (2018-06-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)

PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection
by: Fan Yang, et al.
Published: (2018-12-01)

Myeloproliferative Neoplasms Associated with Mutation in JAK2V617F and Tyrosine Kinase Inhibitors as Therapeutic Strategy
by: Kaveh Tari, et al.
Published: (2015-04-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
by: Jakub Litak, et al.
Published: (2019-10-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
by: Zhuang Y, et al.
Published: (2020-01-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV
by: Gilberto Filaci, et al.
Published: (2018-10-01)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
by: Jing W, et al.
Published: (2016-01-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
by: Jian-ye Zhang, et al.
Published: (2020-05-01)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
by: Weiting Qin, et al.
Published: (2019-10-01)

Etude des homologies phénotypiques et fonctionnelles des lymphocytes B en latence III de l'EBV avec les cellules B régulatrices, implication de l'axe PD-1/PD-L1
by: Auclair, Héloïse
Published: (2017)

mRNA EXPRESSION OF PD-1, PD-L1, AND IMMUNOTHERAPY IN BLADDER CANCER
by: Muhammad Puteh Mauny, et al.
Published: (2021-07-01)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020-06-01)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
by: Liudmila Spirina, et al.
Published: (2021-09-01)

Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B
by: Wenjin Zhang, et al.
Published: (2012-08-01)

PD1/PD1L pathway, HLA-G and T regulatory cells as new markers of immunosuppression in cancers
by: Paulina Własiuk, et al.
Published: (2016-10-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
by: Xueping Wang, et al.
Published: (2020-05-01)

Research Progress of PD-1/PD-L1/2 Pathway in Multiple Myeloma
by: MA Yinjuan, et al.
Published: (2021-06-01)

Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy
by: Christopher Tay, et al.
Published: (2021-12-01)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
by: Tomas Jelinek, et al.
Published: (2018-11-01)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
by: Xin-wei Qiao, et al.
Published: (2020-09-01)

Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
by: Fan Y, et al.
Published: (2016-10-01)

CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival
by: Huazhen Liu, et al.
Published: (2019-02-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
by: Vishwanatha R. A. P. Reddy, et al.
Published: (2019-12-01)

PD-L1 Expression in Mastocytosis
by: Margaret Williams, et al.
Published: (2019-05-01)